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Abstract
We have previously shown that genetic variability in CNR1 is associated with low HDL dyslipidemia in a multigenerational
obesity study cohort of Northern European descent (209 families, median =10 individuals per pedigree). In order to assess
the impact of CNR1 variability on the development of dyslipidemia in the community, we genotyped this locus in all
subjects with class III obesity (body mass index .40 kg/m
2) participating in a population-based biobank of similar ancestry.
Twenty-two haplotype tagging SNPs, capturing the entire CNR1 gene locus plus 15 kb upstream and 5 kb downstream,
were genotyped and tested for association with clinical lipid data. This biobank contains data from 645 morbidly obese
study subjects. In these subjects, a common CNR1 haplotype (H3, frequency 21.1%) is associated with fasting TG and HDL
cholesterol levels (p=0.031 for logTG; p=0.038 for HDL-C; p=0.00376 for log[TG/HDL-C]). The strength of this relationship
increases when the data are adjusted for age, gender, body mass index, diet and physical activity. Mean TG levels were
160670, 155670, and 120660 mg/dL for subjects with 0, 1, and 2 copies of the H3 haplotype. Mean HDL-C levels were
45610, 47610, and 4869 mg/dL, respectively. The H3 CNR1 haplotype appears to exert a protective effect against
development of obesity-related dyslipidemia.
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Introduction
Clinical lipid disorders have enormous public health significance.
Circulating low density lipoprotein cholesterol (LDL-C) levels are
strongly correlated with cardiovascular disease, and pharmacolog-
ical intervention targeted at reducing LDL-C can markedly reduce
risk [1]. High density lipoprotein cholesterol (HDL-C) and fasting
triglyceride (TG) levels are also strong predictors of cardiovascular
disease [2,3]. Data obtained from many diverse sources suggest that
HDL-C may in fact be cardioprotective. Each 1 mg/dL increase in
HDL-C is associated with a 6% reduction in cardiovascular events
[2].Thedecrease inHDL-Clevel that typicallyaccompanies weight
gain is therefore of considerable importance, particularly in the
context of the growing obesity epidemic.
Body mass index (BMI) is inversely correlated with HDL-C
level, and genetic variability in endocannabinergic signaling
clearly influences both of these traits [4,5,6]. We have previously
shown that a functional variant (a nonsynonymous coding SNP) in
fatty acid amide hydrolase (FAAH) is associated with large changes
in circulating HDL-C levels (mean HDL-C=40.5614.7 mg/dL,
39.1610.4 mg/dL and 34.868.1 mg/dL for subjects with 0, 1,
and 2 copies of the variant, p,0.01) [7]. This effect is partly
independent of BMI, and insulin responsiveness [7]. The FAAH
gene product enzymatically inactivates N-arachidonylethanola-
mine (AEA), the primary endogenous CB1 receptor ligand [8].
Genetic variability in the CB1 receptor itself (gene name CNR1)
is also associated with dyslipidemia [4,7]. Our group has
previously shown that a common CNR1 haplotype (15%
frequency in subjects of Northern European ancestry) is associated
with elevated fasting TG levels and reduced levels of HDL-C in
one of the most rigorously phenotyped family-based obesity
cohorts in the U.S. Again, this effect was partly independent of
BMI [4]. Because the relationship between BMI and HDL-C is
curvilinear [9], and because the correlation is most pronounced in
subjects who are extremely obese [9], we characterized the
relationship between dyslipidemia and genetic variability in CNR1
in study subjects with a very high BMI (class III obesity, defined as
BMI.40 kg/m
2).
In the current study, we interrogated the comprehensive
electronic medical record of the Marshfield Clinic Personalized
Medicine Research Project (n=20,000), identified all participants
with a BMI.40 kg/m
2, and genotyped 645 of these individuals
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locus (plus 15 kb upstream and 5 kb downstream). To adjust for
the potential impact of diet and lifestyle, our analytical models
included previously archived data regarding nutrient intake
(percent calories from fat, alcohol intake) and physical activity
(sport, leisure and occupational activity). We report a CNR1
haplotype (21.1% frequency in subjects of Northern European
ancestry) that may protect against the development of low-HDL
dyslipidemia during weight gain.
Methods
Ethics Statement
The current study was conducted in accordance with the
Principles outlined within the Declaration of Helsinki, and all
participants have provided informed written consent. Approval
was obtained from the Institutional Review Board of the
Marshfield Clinic in Wisconsin, and the Institutional Review
Board of Vanderbilt University in Tennessee.
Study Population
This study was conducted using one of the largest population-
based biobank cohorts in the U.S., the Marshfield Clinic
Personalized Medicine Research Project (PMRP) [10,11]. The
PMRP biobank currently contains DNA and secure, encrypted,
electronic medical records for more than 20,000 participants
[9,12]. Subjects within the PMRP biobank were recruited from the
surrounding community, a rural population residing in Central
Wisconsin [13,14]. Like the surrounding community, the cohort is
97% non-Hispanic white. The primary ethnic groups include
German (78%), Irish (17%), English (16%), Norwegian (12%),
Polish (11%), and other Northern European groups. Weight trends
in this region closely mirror those of the non-Hispanic white
population in the National Health and Nutrition Examination
Survey (NHANES).
The gender-stratified distribution of BMI is illustrated in
Figure 1, for the entire PMRP biobank (n=20,000). All biobank
participants with class III obesity (BMI.40 kg/m
2) were identified
for the current study (n=645). The current study population is
skewed toward females (i.e., 168 male and 477 female participants
with BMI.40 kg/m
2). This female preponderance reflects two
factors. First, female patients opted to participate in the PMRP
biobank at a slightly higher rate than male patients (58% versus
42%) [10,15]. Second, within our target community, extreme
obesity is more prevalent in females than in males (7.8% versus
4.4%). General subject characteristics are summarized in Table 1.
Phenotyping
All clinical lipid data were electronically extracted from the
biobank database, for each of the 645 study subjects. These data
reflect longitudinal lipid data collected during the course of routine
clinical care, and imported from the comprehensive electronic
medical record into the PMRP database. Each lipid trait was then
expressed as a median baseline lipid value for every individual.
Median lipid levels (Cholesterol, LDL, HDL, and TG) represented
our primary endpoints, available on all 645 subjects included in
this study.
Because clinical lipid data can be markedly altered by co-
morbidity and/or medication use, we have also developed an
alternate phenotype, a modeled lipid trait constructed by
censoring the longitudinal lipid data for each individual at the
first medical record date linked to a relevant co-morbidity (e.g.,
diabetes mellitus) or lipid modifying medication (e.g., atorvastatin).
Our approach has been published [9]. Of the 645 subjects
included in the current study, 306 had been exposed to at least one
lipid medication during the course of their routine clinical care,
289 (44.8%) had been exposed to statins, 32 (5.0%) to fibric acid
derivatives, and 84 (13.0%) to prescription strength niacin. Thus,
our secondary traits (i.e., modeled lipid levels) were available for
slightly less than half of the cohort (n=288 with modeled HDL,
n=270 for modeled TGs, and n=261 for modeled LDL).
Clinical Covariates
For each PMRP participant, BMI was accurately defined at the
time of study entry (Figure 1). Height was obtained for each
participant using a stadiometer according to standard methods.
Weights were also collected at entry, using a beam balance scale
according to standard methods. Measurements occurred after the
study participant had removed their shoes, hats, and bulky clothing,
such ascoatsandsweaters.Scaleswereplacedinthe ‘‘zero’’position
prior to weighing. Weights were recorded to the nearest 1/4 pound
(100 grams). BMI was then calculated from the measured height
andweightdata,bydividing weightinkilograms byheightinmeters
squared [16]. Weights are also available longitudinally, over the
course of many years in the clinical notes.
After enrollment, food frequency questionnaires (FFQs) were
used to assess dietary intake. Compared to other epidemiologic
methodologies (including weighed food records and 24-hour
dietary recalls), FFQs are more representative of usual intake
and less expensive to implement, as they are usually self-
administered [17,18]. The selected FFQ for the PMRP, the Diet
History Questionnaire (DHQ) (http://riskfactor.cancer.gov/
DHQ), was developed by researchers at the National Cancer
Institute and has been shown to be superior to the commonly used
Willet FFQ and similar to the Block FFQ for estimating absolute
nutrient intakes [19,20,21,22,23,24,25]. The DHQ comprises 124
separate food items and asks about portion sizes for most foods. In
addition, there are ten questions regarding nutrient supplement
intake. The DHQ was printed and scanned by Optimum
Solutions (CA, USA). After scanning, the data from the
questionnaires were stored in ASCII format and uploaded into a
nutrient analysis software package. Diet*Calc software, available
from the NIH, was used to convert DHQ data into macronutrient
intake [26]. The relationship between BMI and dietary fat intake
(% of daily calories due to fat) is shown in Figure 2.
Physical activity was also quantified for use in the current study.
Standardized surveys are the most practical approach for assessing
activity level in large populations. A self-administered physical
activity questionnaire, the ARIC/Baecke questionnaire, was
mailed to each biobank participant. The ARIC/Baecke question-
naire represents a modified version of the original Baecke
Questionnaire [27], comprised of 16 questions, generating three
indices of activity: 1) a work index, 2) a sport index, and 3) a
leisure-time index [28]. This questionnaire has previously been
validated with physiological methods [28].
Genotyping
Haplotype tagging SNPs were identified using our previously
published approach [4]. Chromosomal position of the CNR1 gene
was obtained from the UCSC human genome browser (http://
genome.cse.ucsc.edu/cgi-bin/hgGateway). SNPs within the region
of interest were downloaded from the International Human
Haplotype Map for the Centre d’Etude du Polymorphisms
Humain (CEPH) and entered into Haploview for an analysis of
linkage disequilibrium (LD) and tag SNP assignment. The extent
of LD across this region was quatified [29] and tag SNPs
were identified using Tagger [30]. Cladograms were constru-
cted applying the confidence interval method implemented in
CNR1 Gene Predicts Lipid Changes
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BMI.40 kg/m
2 (n=477 female participants, and 168 male participants) were included in the current study cohort.
doi:10.1371/journal.pone.0015779.g001
Table 1. Patient characteristics.
Female (N=477) Male (N=168)
Mean ± SD Mean ± SD
Covariates Demographic Information:
Age (years) 48.6614.5 52.1615.1
Weight (lbs) 263.7636.6 303.4636.9
Height (inches) 63.963.1 69.462.9
BMI (kg/m
2) 45.465.1 44.364.2
Dietary Intake:
Total cal. from food (Kcal) 1763.361018.8 2322.461281.2
Cal. from protein (Kcal) 71.8643.3 97.5659.6
Cal. from fat (Kcal) 65.7642.9 89.17655.95
Cal. from carbohydrate (Kcal) 225.46132.9 275.746153.69
Alcohol consumption (grams) 3.7623.2 9.9620.2
Physical Activity:
Work Index 2.660.7 2.860.8
Sport Index 1.860.5 1.960.5
Leisure Index 2.460.6 2.260.6
Endpoints Lipid Phenotypes:
Median T CHOL (mg/dL) 193.0631.2 192.3631.3
Median LDL-C (mg/dL) 116.7626.5 116.5627.5
Median HDL-C (mg/dL) 48.3610.5 40.967.8
Median TG (mg/dL) 151.4669.2 175.7675.7
T CHOL: total cholesterol; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; TG: triglyceride.
doi:10.1371/journal.pone.0015779.t001
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approach to successfully identify SNPs associated with dysplipide-
mia in familes of Northern European descent [4]. The block
structure for our region of interest is shown in Figure 3, based
upon pairwise correlation (D’) in our current cohort. This
structure is similar to the structure in our prior report [4].
Genotyping was conducted using commercial Taqman Allelic
discrimination assays available through Applied Biosystems, Inc.
(ABI, Foster City, CA, USA). This method allows direct detection
of a thermocycling product by the release of a fluorophor as a
result of the Taq polymerase’s 59 exonuclease activity [32]. The
individual allele specific oligonucleotide assays are shown in
Table 2. All assays were performed according to the manufac-
turer’s specifications (ABI): After a run-in period (50.0u for 2
minutes followed by 95.0u for 10 minutes), each reaction was
cycled forty times (92.0u for 15 seconds followed by 60.0u for 1
minute) then held at 4.0u until the fluorescence was read by an
ABI 7700 Sequence Detector. Each assay contained two different
Taqman probes, uniquely labeled to bind to separate (major versus
minor) alleles. Each probe consisted of an oligonucleotide with a 59
reporter dye and 39 quencher dye. When intact, the proximity of
the quencher to the reporter suppresses the fluorescence of the
fluorophor. If the probe binds the allele, then taq polymerase
cleaves the quencher from the probe, resulting in increased
fluorescence. The fluorescent signal was read and quantified by
the ABI 7700 Sequence Detector, and the manufacturer-supplied
software (ABI) interpreted the relative fluorescent levels of the dye
for each sample, calculating the final genotype.
Statistical Analyses
Genotype-phenotype association tests were conducted using
median lipid values as the primary endpoint. The following traits
were available on all 645 subjects included in this study: median
total cholesterol level, median LDL cholesterol level, median HDL
cholesterol level, median TG level, and median TG/HDL-C ratio.
Because the TG distribution was skewed, TGs were log trans-
formed. Statistical analyses included tests for association of lipids
with single SNPs and haplotypes. All tests involving our primary
endpoints were performed using PLINK, a free, open-source
genetic analysis toolset (http://pngu.mgh.harvard.edu/ &purcell/
plink/) [33]. This platform was selected based on its efficiency,
flexibility and ease of application. The --freq option was used to
calculate minor allele frequency (MAF), and the --hardy option
was used to calculate Hardy Weinberg equilibrium (HWE). No
SNPs in this study significantly deviated from HWE.
A linear regression model was applied to test the relationship
between each SNP and the median lipid traits representing our
primary endpoint using the --linear option in PLINK. Asymp-
totic p-values were reported. Initially, 3 inheritance modes were
tested: additive, dominant and recessive. An additive model, which
is the default mode in PLINK, fit our data best, and an additive
model was therefore chosen for all subsequent analyses. We also
estimated the influence of environmental factors, dietary intake
and physical activity by including them as covariates in the linear
regression model using the --covar option.
As noted above, modeled lipid traits were also developed for a
set of secondary analyses. For these analyses, longitudinal lipid
data were right censored at the first mention of a relevant co-
morbidity or medication known to modify lipid homeostasis,
according to our previously published approach [9]. These
secondary traits were available for slightly less than half of the
cohort (n=288 with modeled HDL, n=270 for modeled TGs,
and n=261 for modeled LDL). In a confirmatory series of tests,
they were analyzed for association with single SNPs using a non-
parametric approach (Kruskal-Wallis test). When these confirma-
tory tests localized all SNP associations to the single block of LD
Figure 2. Scatterplot showing the relationship between BMI and dietary fat intake for PMRP participants. Using the entire PMRP
biobank (n=20,000), percentage of daily calories due to fat has been plotted against BMI at the time of study entry. Trend-line is added (r=0.086).
doi:10.1371/journal.pone.0015779.g002
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using only that locus.
Haplotypes were estimated using 6 tag SNPs contained within
our 15 kb locus of interest, by applying standard E-M algorithms
located in the --hap option of PLINK. A linear regression model
was applied to test each haplotype (vs all other haplotypes), using
the --hap-linear option. All haplotypes with frequency $5%
were included in these analyses. Permutation testing was applied to
reduce the likelihood that our reported associations were observed
simply by chance. Results are reported in both unadjusted and
adjusted format (adjusting for age, gender, BMI, physical activity
and dietary fat intake).
Results
A total of 168 male and 477 female biobank participants with
class III obesity (BMI.40 kg/m
2) were included in this study. Of
these, 70 males and 162 females were diabetic. Participant
characteristics are summarized in Table 1, including lipid
phenotypes, dietary intake and physical activity. Mean age for
maleand femaleparticipants were52.1615.1 and 48.7614.6 years,
respectively. The PMRP claims 97% Northern European ancestry.
Genotyping was performed on 645 DNA samples using the 22
haplotype tagging SNPs listed in Table 2. All SNPs followed
Hardy-Weinberg (H-W) equilibrium in this cohort, and the
observed allele frequencies compared favorably with published
frequencies [34].
Original region of interest
The CNR1 gene is found on the reverse strand of chromosome
6. As mentioned above, and in our previous report [4], this locus
contains two discrete blocks of LD. The coding region is contained
in a single exon, located in the downstream block [4]. The second
block, proposed to contain additional noncoding exons [35], is
located further upstream.
Figure 3. Chromosomal location for CNR1, and linkage disequilibrium (LD) structure within the PMRP database. The chromosome
position of the CNR1 gene was obtained from the UCSC human genome browser for the entire gene plus 15 kb upstream and 5 kb downstream
(http://genome.ucsc.edu/). SNPs within the identified region were quantified within our study cohort (n=645) and entered into Haploview for an
assessment of LD and tagSNP assignment. Applying the confidence interval method implemented in Haploview version 4.0, we observed two
haplotype blocks covering the entire region of interest. CNR1: Cannabinoid receptor 1; LD: Linkage disequilibrium; UCSC: University of California,
Santa Cruz.
doi:10.1371/journal.pone.0015779.g003
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the downstream block and plasma TG level, the trait most strongly
associated with CNR1 in our prior work [4]. As illustrated in
Table 3, rs806372 (a SNP in the putative promoter region of
CNR1) shows suggestive association with logTG. As shown, the
strength of this association increases when the data are adjusted for
dietary intake and physical activity. The strength of the association
did not change when the data were further adjusted for age,
gender, BMI, carbohydrate intake and alcohol consumption
(p=0.063, n=578, data not shown). Three inheritance modes
were tested (not shown). As in our prior work, an additive mode
was the best predictor of association. All subsequent analyses used
this mode.
Expanded region of interest
The transcription start site for the CNR1 is thought to reside
within the block of LD tagged by the 8 SNPs analyzed above
(rs806372, rs806370, rs806369, rs1049353, rs12720071, rs806368,
rs806366, rs806365). However, at least one prior report has
suggested an alternate transcription start site approximately 15 kb
upstream [4,35]. We therefore also tested our traits of interest for
association with an additional 14 tagging SNPs capturing the LD
contained within a second haplotype block located upstream
(Figure 3). In these analyses, total cholesterol was tested, along
with LDL-C, HDL-C, logTG, and log[TG/HDL]. As shown in
Table 4, these additional SNPs do not provide any indication of
further association with lipid traits in the 15 kb upstream of
rs806372.
The magnitude of effect was calculated for all variants that
showed associations with lipid traits. Subjects with 0, 1 or 2 copies
of the G-allele at rs12720071 have an LDL level of 117.5627.0,
112.8623.6, and 102.7623.3 mg/dL, respectively. Subjects with
0, 1, or 2 copies of the C-allele at rs806368 have a mean TG level
of 153.7670.4, 163.1674.0, and 184.36100.9 mg/dL; and
subjects with 0, 1 or 2 copies of the C-allele of rs806372 have a
mean TG level of 154.1670.7, 171.4675.6, and 138.8647.8 mg/
dL.
To be certain that we were not missing any additional genetic
association upstream, we reanalyzed these data using a more
refined phenotype (i.e., modeled lipid traits, censored for co-
morbidity and lipid modifying medication use) and an alternate
statistical approach (i.e., non-parametric analyses using a Kruskal-
Wallis test). As shown in Table 5, these alternate approaches
failed to reveal any further association with lipids, for tagging
SNPs upstream to rs806372. This approach did, however, resolve
additional associations with HDL-C, located in our original region
of interest (i.e., tagged by the original SNPs) [4].
Haplotype analyses
Haplotypes often provide greater statistical power than single-
marker analyses, for genotype-phenotype association studies. We
have previously shown that tagging SNPs capturing the linkage
structure defined by physical position 88,901,306 to 88,916,775
are adequate to resolve an association with obesity-related
dylipidemia [4]. Our single SNP analyses outlined above indicate
that characterization of this region is sufficient to explain the entire
association between CNR1 and altered lipid homeostasis. We
therefore focused all subsequent analyses on the block of LD
containing those specific SNPs [4]. Those 6 SNPs are highlighted
in Table 2 and Figure 3. It should be noted that Tables 3–5
demonstrate univariate association between lipid traits and one
additional SNP slightly upstream, rs806372. This SNP is in
complete LD with haplotype H4, as shown below. Extending the
region haplotyped to include it would therefore have been
redundant.
Thus, haplotype designation followed Baye’s original report [4].
Haplotype frequencies observed in the current population were
again comparable to other cohorts of similar Northern European
ancestry. Table 6 demonstrates that a common CNR1 haplotype
(H3, frequency 21%), is associated with fasting TG and HDL-C
levels (p=0.0307 for logTG; p=0.0382 for HDL-C; p=0.0038
for log[TG/HDL-C]). The results are presented in both
unadjusted and adjusted format (adjusting for age, gender, BMI,
physical activity and dietary fat intake). To correct for testing
multiple hypotheses, we also conducted permutation testing
(applying 1000 permutations) using software available in PLINK.
By preserving the correlational structure between tag SNPs, this
approach provides a less stringent correction than a Bonferroni
correction. Because the association between H3 and obesity
related dyslipidemia persists after permutation testing (empirical
p=0.0180 for log[TG/HDL-C]), it is very unlikely that these
associations were observed by chance.
Table 7 suggests that these associations are clinically
significant. Mean TG levels were 160670 mg/dL, 155670 mg/
dL and 120660 mg/dL for subjects with 0, 1, and 2 copies of the
H3 haplotype. Mean HDL-C levels were 45610 mg/dL,
47610 mg/dL and 4869 mg/dL, respectively. Even a modest
1 mg/dL increase in HDL-C is associated with a 6% reduction in
vascular events [2]. Thus, our findings suggest that the H3
Table 2. Tag SNP minor allele frequencies.
SNP Assay (TaqMan) MAF
1 reported MAF
2 observed
806365 C__1652594 0.43 (T) 0.40 (T)
806366 C___1652593 0.48 (C) 0.48 (C)
806368 C___8943804 0.19(C) 0.20 (C)
12720071 C___30749291 0.11 (C) 0.09 (G)
1049353 C___1652590 0.26(A) 0.31 (A)
806369 C___8943784 0.32 (T) 0.27 (T)
806370 C___1652589 0.15 (T) 0.09 (T)
806372 C__8943783 0.15 (C) 0.12 (C)
806376 C__1652586 0.43 (C) 0.50 (C)
806377 C__1652585 0.48 (C) 0.48 (T)
2023239 C__11600616 0.17 (C) 0.17 (C)
806379 C__1652584 0.44 (T) 0.48 (T)
6928499 C__30749294 0.18 (C) 0.16 (C)
6928813 C__30749295 0.17 (G) 0.16 (G)
9444584 C__30598869 0.2 (T) 0.18 (T)
9450898 C__30274410 0.16 (T) 0.16 (T)
7752758 C__9863393 0.11 (G) 0.12 (G)
12528858 C__9863392 0.05 (G) 0.07 (G)
12205430 C__30749298 0.19 (C) 0.21 (C)
6454673 C__27392043 0.26 (A) 0.30 (A)
6454674 C__11418433 0.29 (G) 0.31 (G)
6454676 C__28979979 0.08 (A) 0.11 (A)
All SNPs used for haplotype construction are bold.
1anticipated MAF based on CEPH cohort (abstracted from ABI website/product
catalog).
2observed MAF within 645 PMRP study subjects with Class 3 Obesity
(BMI.40 kg/m
2).
doi:10.1371/journal.pone.0015779.t002
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further study during weight gain.
Discussion
The current study demonstrates that genetic variability in
CNR1 contributes to several derangements in lipid homeostasis
known to accompany weight gain. We report a CNR1 haplotype
(H3, frequency 21.1%) associated with fasting TG and HDL-C
levels in 645 study subjects with class III obesity, nested within one
of the largest population-based biobanks in the U.S. We localize
the genetic effect to a single block of LD containing the CNR1
coding region, and we demonstrate that this effect is only partly
dependent upon nutrient intake and physical activity. Our findings
Table 3. Replication and refinement of the model (p-values are shown, calculated using a linear regression model in PLINK).
Log TG [additive] p-value, adjusted by:
SNP MAF Without Adjustment BMI
Grams EtOH
consumption Percent of kCal from Fat Sport Index
RS806365 0.402 0.863 0.874 0.946 0.954 0.963
RS806366 0.48 0.109 0.108 0.116 0.107 0.066
RS806368 0.202 0.071 0.071 0.065 0.061 0.048
RS12720071 0.086 0.418 0.419 0.382 0.371 0.421
RS1049353 0.312 0.863 0.863 0.788 0.82 0.985
RS806369 0.271 0.447 0.447 0.449 0.46 0.614
RS806370 0.088 0.295 0.299 0.273 0.263 0.192
RS806372 0.122 0.045 0.044 0.037 0.035 0.027
doi:10.1371/journal.pone.0015779.t003
Table 4. Association between median lipid traits and single
SNPs, using an extended region of interest (p-values from a
linear regression model in PLINK).
Additive Mode p-value
SNP MAF T CHOL LDL-C HDL-C Log TG
Log (TG/
HDL-C)
RS806365 0.402 0.250 0.761 0.651 0.857 0.970
RS806366 0.480 0.741 0.430 0.452 0.061 0.060
RS806368 0.202 0.437 0.124 0.204 0.041 0.031
RS12720071 0.086 0.032 0.040 0.202 0.375 0.175
RS1049353 0.312 0.159 0.527 0.707 0.994 0.860
RS806369 0.271 0.503 0.203 0.467 0.633 0.569
RS806370 0.088 0.552 0.739 0.814 0.164 0.232
RS806372 0.122 0.889 0.615 0.219 0.020 0.023
RS806376 0.499 0.814 0.091 0.872 0.857 0.861
RS806377 0.483 0.848 0.083 0.692 0.831 0.899
RS2023239 0.166 0.879 0.583 0.910 0.918 0.922
RS806379 0.479 0.874 0.249 0.898 0.716 0.737
RS6928499 0.164 0.870 0.497 0.984 0.904 0.977
RS6928813 0.164 0.870 0.483 0.974 0.930 0.962
RS9444584 0.178 0.792 0.315 0.686 0.830 0.839
RS9450898 0.164 0.874 0.462 0.928 0.944 0.973
RS7752758 0.125 0.585 0.394 0.863 0.935 0.958
RS12528858 0.066 0.842 0.882 0.083 0.449 0.198
RS12205430 0.213 0.414 0.823 0.076 0.738 0.296
RS6454673 0.302 0.842 0.425 0.342 0.893 0.599
RS6454674 0.315 0.739 0.369 0.377 0.859 0.815
RS6454676 0.107 0.248 0.151 0.916 0.975 0.858
doi:10.1371/journal.pone.0015779.t004
Table 5. Association between modeled lipid trait and single
SNPs, over the same extended region of interest shown in
Table 4 (Kruskal-Wallis p-values are shown).
Kruskal-Wallis p-value
SNP T CHOL LDL-C HDL-C TG
RS806365 0.524 0.479 0.909 0.772
RS806366 0.731 0.213 0.847 0.250
RS806368 0.881 0.710 0.043 0.103
RS12720071 0.460 0.433 0.029 0.264
RS1049353 0.155 0.095 0.046 0.804
RS806369 0.892 0.215 0.615 0.352
RS806370 0.399 0.448 0.518 0.114
RS806372 0.076 0.375 0.218 0.028
RS806376 0.468 0.856 0.808 0.282
RS806377 0.480 0.671 0.962 0.491
RS2023239 0.846 0.207 0.192 0.906
RS806379 0.287 0.755 0.901 0.611
RS6928499 0.881 0.212 0.194 0.904
RS6928813 0.880 0.212 0.200 0.908
RS9444584 0.794 0.341 0.189 0.759
RS9450898 0.886 0.208 0.210 0.911
RS7752758 0.728 0.078 0.460 0.901
RS12528858 0.371 0.480 0.975 0.643
RS12205430 0.137 0.461 0.354 0.567
RS6454673 0.345 0.948 0.208 0.716
RS6454674 0.417 0.972 0.154 0.411
RS6454676 0.366 0.040 0.465 0.260
doi:10.1371/journal.pone.0015779.t005
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Mechanism
Endocannabinergic signaling plays a critical role in the
regulation of energy metabolism. Both animal studies and clinical
trials have suggested a relationship between CNR1 and body
composition [36,37,38]. However, studies characterizing this
relationship have yielded controversial observations from different
populations [39,40,41,42]. One of the most well-characterized
longitudinal cohort studies in the U.S, the Framingham Heart
Study, recently failed to observe any association between CNR1
and obesity [42]. In retrospect, the impact of variable endocanna-
binergic signaling on weight gain in some cohorts may have been
secondary to an underlying relationship between CNR1 and lipid
homeostasis, perhaps related to an alteration in the hepatic
efficiency of fatty acid beta oxidation, an alteration in fatty acid
biosynthesis, or a combination of both [37].
Recently, a number of lipid and lipoprotein phenotypes have
been associated with variability in CNR1, and the eCB signaling
pathway in general [4,7]. Our data are consistent with these
reports. Endocannabinoids clearly modulate lipid traits through
mechanisms other than enhanced food intake [43,44]. For
example, clinical trials conducted with CB1 blockers in subjects
of European ancestry have revealed a greater improvement in
metabolic parameters than anticipated based on weight loss alone
[38,45]. In an analysis of covariance, which corrected for weight
loss through standard regression methods, patients taking CB1
blockers developed an increase in HDL-C and a decrease in
fasting TG levels more than twice that anticipated based upon
change in weight [38,45]. Further, CNR1 knockout mice maintain
a favorable lipid profile during high-fat diet [36,37]. Altered
mRNA expression in animal models and cell culture systems
suggest an involvement of CNR1 in both lipogenesis and lipid
transportation [46,47,48]. While hepatocyte-specific CNR1
knockout mice gain weight at a rate similar to their wild type
littermates, they are resistant to dyslipidemia in a manner
comparable with a lean phenotype [37]. While some data indicate
that CB1 activation directly alters hepatic lipogenesis (increased
acetylCoA carboxylase activity, increased fatty acid synthase
activity, and decreased fatty acid b-oxidation) [37], other data
suggest a role for CB1 in the modulation of cholesterol uptake
and/or efflux [49]. The effect of CB1 activity on cholesterol
transport may be mediated through SRB1 or ABCG1 [46]
The role of environment
To date, common variants in biological candidate genes have
only explained a small fraction (typically less than 5%) of the
variance in complex traits such as dyslipidemia [50,51]. Although
it is reassuring to note that most associations identified in genome-
wide scanning efforts reflect biologically plausible mechanisms,
even highly heritable traits such as height (H
2
[Height] ,0.8) would
require nearly 10
5 discrete variants to explain the phenotype based
on current statistical modeling [52]. Heritability for HDL-C level
is robust and comparable to height (H
2
[HDL-C] ,0.7 [7]). Thus, it
is plausible (and in fact likely) that gene-environment (GxE)
interactions strongly influence this trait [53,54].
For CNR1 specifically, analyses based on GxE have improved
predictive power in the context of neuropsychiatric endpoints [55].
Nutrient intake is clearly a strong contributor to CNR1-
environment interactions. In hepatocyte specific CNR1 knock-
down animals, the metabolic effects are only present when animals
are fed with a high-fat diet, not a chow diet [37]. In the current
study, CNR1 interacts with dietary intake (percent calories due to
fat) and vigorous physical activity (the sport index from a
standardized survey instrument) to modulate lipid levels. Statistical
adjustment for diet and physical activity strongly influences the
association between CNR1 and TG level (as illustrated in
Table 7), while such an adjustment has little effect on the
relationship between CNR1 and HDL-C. This provides further
Table 6. Association between CNR1 haplotype and median lipid traits (p-values are shown, calculated using a linear regression
model in PLINK).
T Chol LDL-C HDL-C Log TG Log (TG/HDL-C)
Haplotype{ (59-39) 1 Freq. Unadj. Adj.* Unadj. Adj.* Unadj. Adj.* Unadj. Adj.* Unadj. Adj.*
H1 CCAATT 0.302 0.122 0.185 0.375 0.563 0.733 0.792 0.950 0.712 0.907 0.639
H2 CTGATC 0.267 0.766 0.659 0.315 0.187 0.277 0.471 0.864 0.878 0.428 0.778
H3 CCGATC 0.211 0.453 0.533 0.938 0.860 0.0382 0.036 0.0307 0.0093 0.00376 0.00349
H4 TCGACT 0.114 0.541 0.539 0.877 0.952 0.480 0.556 0.117 0.071 0.108 0.113
H5 CCGGCT 0.085 0.043 0.036 0.068 0.062 0.360 0.611 0.454 0.766 0.369 0.560
*adjusted by age, gender, BMI, calories from fat and sport index.
{Designation in Tes Baye paper (2008).
1SNPs that used for haplotype construction (59-39): rs806370, rs806369, rs1049353, rs12720071, rs806368, rs806366.
doi:10.1371/journal.pone.0015779.t006
Table 7. Effect of H3 haplocopy on lipid traits (mean 6 SD).
Haplotype Copies of Haplotype Freq. HDL-C (mg/dL) TG (mg/dL) BMI (kg/m
2)
H3 0 0.63 45.9610.4 160.1671.7 45.265.1
1 0.33 47.6610.3 155.8670.1 45.164.7
2 0.04 48.269.9 120.4661.2 44.964.8
doi:10.1371/journal.pone.0015779.t007
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fasting TG through a combination of central (appetite-related) and
peripheral (lipid homeostatic) mechanisms [4], while genetic
variation in CNR1 alters HDL-C level through a more direct
effect localized primarily to the liver [36,38].
Causative variants
Overall, we observed a number of similarities between our
currentresults,and findings reported previously inmutigenerational
families of Northern European descent [4]. For example, rs806368,
a SNP in the 39-UTR of CNR1, is associated with fasting TG level
in both cohorts. Further, the H4 haplotype was strongly associated
with TGs in the original cohort and marginally associated with TGs
in the current cohort (a cohort limited to the severely obese). Our
most notable dissimilarity would be the observation that a different
haplotype, H3, was associated with HDL-C in the current cohort
only. Because the relationship between BMI and HDL-C is
curvilinear [9], the protective effect of H3 against reduction in
HDL-Clevelmayonlybeevidentinsubjectswithanextremelyhigh
BMI. It is important to note, however, that this relationship is not
driven by a direct effect of CNR1 on obesity. CNR1 haplotypes
were not associated with BMI in either cohort [4].
Our findings reveal that severely obese study subjects with 0, 1
and 2 copies of the H3 haplotype have mean HDL-C levels of
45610, 47610, and 4869 mg/dL, respectively. Conversely,
subjects with 0, 1 or 2 copies of H3 haplotype have mean TG
levels of 160670, 155670, and 120660 mg/dL, respectively.
Although H3 appears to represent a protective haplotype (high
HDL-C and low TG), the causative variants underlying the
relationship between CNR1 and obesity-related dyslipidemia
remain unknown. H3 is likely only in partial linkage (i.e.,
D’,1.0) with the causal variants, and the underlying functional
alleles are probably both common and rare [52,56]. One or more
structural variants may also be contributing [57]. Repeating
elements are quite common in CNR1.
It is becoming increasingly clear that the genetic control over
most complex traits is due to a combination of common and rare
variants, and that the rare variants contributing to these
interactions exhibit considerably larger effect sizes than most
common variants [52]. Thus, rare variants are likely to be
responsible for most of the missing heritability underlying complex
traits like circulating lipid levels. Future efforts must therefore be
directed toward sequencing the CNR1 gene in representative
subsets enriched for the traits of interest [58] and the marker(s)
most strongly associated with those traits.
Outlook
Human obesity is often co-morbid with metabolic disturbances
that are ultimately more debilitating and life-threatening than
obesity itself. Derangements in lipid homeostasis accompanying
weight gain are due in part to genetic variation in CNR1. Efforts
to re-sequence this gene in relevant cohorts will improve our
understanding of dyslipidemia.
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